NCT01691989已完成3 期
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III STUDY TO ASSESS THE EFFICACY,SAFETY AND TOLERABILITY OF ALEGLITAZAR ADDED TO A SU OR ADDED TO A SU IN COMBINATION WITH MET IN PATIENTS WITH T2D INADEQUATELY CONTROLLED WITH SU MONOTHERAPY OR WITH SU + METFORMIN COMBINATION THERAPY
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 197
- 主要终点
- Change from baseline in hemoglobin HbA1c
研究概览
简要总结
This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar compared with placebo when added to a sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy in patients with type 2 diabetes mellitus who are inadequately controlled with sulfonylurea alone or sulfonylurea plus metformin therapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >/=18 years of age
- •Diagnosis of diabetes mellitus, type 2
- •Patients treated with stable sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 12 weeks prior to screening
- •HbA1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
- •Fasting plasma glucose </=240 mg/dL at pre-randomization visit
- •Agreement to maintain diet and exercise habits during the study
排除标准
- •Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
- •Any previous treatment with thiazolidinedione or a dual PPAR agonist
- •Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
- •Any anti-hyperglycemic medication other than sulfonylurea alone or in combination with metformin within 12 weeks prior to screening
- •Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening
研究组 & 干预措施
aleglitazar
Experimental
干预措施: aleglitazar (Drug)
placebo
Experimental
干预措施: placebo (Drug)
结局指标
主要结局
Change from baseline in hemoglobin HbA1c
时间窗: From baseline to week 26
次要结局
- Responder rate as defined of hemoglobin HbAc1 <7.0% (<6.5%)(From baseline to week 26)
- Change from baseline in homeostatic index of insulin sensitivity (HOMA-IS)(From baseline to week 26)
- Change from baseline in markers of insulin sensitivity and cardiovascular risk(From baseline to week 26)
- Safety: incidence of adverse events(30 weeks (26 weeks treatment and 4 weeks follow-up))
- Change in lipid profile(From baseline to week 26)
- Change from baseline in fasting plasma glucose(From baseline to week 26)
研究者
相似试验
已完成
3 期
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin AloneDiabetes Mellitus Type 2NCT01691846Hoffmann-La Roche200
已完成
3 期
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic TherapyDiabetes Mellitus Type 2NCT01691755Hoffmann-La Roche196
已完成
3 期
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin MonotherapyDiabetes Mellitus Type 2NCT01871415Hoffmann-La Roche7
已完成
1 期
A Study of RG1662 in Individuals With Down SyndromeDown SyndromeNCT01436955Hoffmann-La Roche35
终止
1 期
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and ComorbiditiesB-Cell Chronic Lymphocytic LeukemiaNCT02336048Hoffmann-La Roche38